DISCRIMINATION BETWEEN NORMAL, HYPERPLASTIC AND MALIGNANT HUMAN PROSTATIC TISSUES BY ENZYMATIC PROFILES

A relative enzymatic index has been developed which differentiates normal, hyperplastic (BPH) and malignant human prostatic tissues. Enzymatic activities wre calculated at Vmax conditions in 10 normal, 14 BPH [benign prostatic hypertrophy] and 11 carcinoma samples. Five enzymes have been assayed: 5.alpha.-reductase, 3.alpha.-hydroxysteroid oxidoreductase [3.alpha.-HSOR], 3.beta.-hydroxysteroid oxidoreductase [3.beta.-HSOR] 17.beta.-hydroxysteroid oxidoredcutase and acid phosphtase. Teh following observations were made when comparing individual enzymatic activities between the 3 tissue groups: mean 5.alpha.-reductase activity was lower in carcinoma than in both normal prostate and BPH (P < 0.05), mean 3.alpha.-hydroxysteroid oxidoreductase and 3.beta.-hydroxysteroid oxidoreductase activities were greater in caricnoma than in BPH (P < 0.05) and mean acid phosphatase actvity was higher in BPH than in both normal prostate and carcinoma (P < 0.01). The absolute enzymatic activities were then expressed as relative activiites by dividing each absolute value by teh mean value for that enzyme in normal prostatic tissue. Relative enzymatic activities were used to derive the ratio: (5.alpha.-reductase .times. acid phosphatase/3.alpha.-HSOR .times. 3.beta.-HSOR). The mean value of this ratio was statistically different in normal, BPH and carcinoma tissue (P < 0.01). The mean value was 3.6 times higher in BPH than in normal tissue, and was 3.8 times higher in normal tissue than in carcinoma. Apparently, BPH and carcinoma diverse in opposite directions biochemically from normal prostatic growth and supports histologic evidence that the 2 neoplastic conditions have a different pathogenesis rather than being part of the same disease spectrum.